Impact Biomedical (IBO) Research & Development (2022 - 2026)
Impact Biomedical's (IBO) quarterly Research & Development came in at $1000.0 in Q1 2026, down 94.74% YoY from $19000.0 in Q1 2025, and down 50.0% on a QoQ basis from $2000.0 in Q3 2025.
Impact Biomedical (IBO) Research & Development (2022 - 2026) Analysis & Trends
Impact Biomedical (IBO) has 5 years of Research & Development data on file, last reported at $1000.0 in Q1 2026.
- Quarterly Research & Development fell 94.74% year-over-year to $1000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $23000.0 (down 92.04% YoY) and the FY2024 annual result came in at $278000.0, up 327.69% from the prior year.
- Research & Development slipped to $1000.0 in Q1 2026, from $2000.0 in the prior quarter.
- In the past five years, Research & Development ranged from a high of $522000.0 in Q4 2022 to a low of -$990000.0 in Q4 2023.
- A 5-year average of $55266.7 and a median of $18000.0 in 2024 frame the typical range for Research & Development.
- Annual changes were most pronounced in 2023 — Research & Development plunged 289.66% — and 2024, when it soared 2611.76%.
- Tracing IBO's Research & Development over 5 years: stood at $522000.0 in 2022, then sank by 289.66% to -$990000.0 in 2023, then jumped by 78.89% to -$209000.0 in 2024, then jumped by 100.96% to $2000.0 in 2025, then slumped by 50.0% to $1000.0 in 2026.
- The last three Research & Development figures came in at $1000.0 (Q1 2026), $2000.0 (Q3 2025), and $1000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.79 Bn | 130.93 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 56.04 Bn | 50.91 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 42.05 Bn | 36.95 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 31.71 Bn | 28.40 Bn | 992.69 Mn | 413.13 Mn |
| 7 | BioNTech SE | 27.66 Bn | 9.26 Bn | 668.28 Mn | -588.31 Mn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 210.03 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 97.90 Mn |
| 10 | Impact Biomedical | 49.54 Mn | 49.53 Mn | 2,000.00 | 76,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 76,000.00 |
| Mar 31, 2026 | 1,000.00 |
| Sep 30, 2025 | 2,000.00 |
| Jun 30, 2025 | 1,000.00 |
| Mar 31, 2025 | 19,000.00 |
| Dec 31, 2024 | -209,000.00 |
| Sep 30, 2024 | 461,000.00 |
| Jun 30, 2024 | 18,000.00 |
| Mar 31, 2024 | 183,000.00 |
| Dec 31, 2023 | -990,000.00 |
| Sep 30, 2023 | 17,000.00 |
| Jun 30, 2023 | 10,000.00 |
| Mar 31, 2023 | 258,000.00 |
| Dec 31, 2022 | 522,000.00 |
| Sep 30, 2022 | 330,000.00 |
| Jun 30, 2022 | 206,000.00 |